Skip to content

Valneva

  • Über uns
    Über uns Advancing vaccines for better lives Mehr lesen
    • Unsere Strategie
    • Unsere Verantwortung
    • Unser Team
  • Produkte
    Produkte Focusing on vaccines for infectious diseases with major unmet needs Mehr lesen
    • Japanische Enzephalitis-Impfstoff
    • Cholera-Impfstoff
    • COVID-19 Impfstoff
    • Marketing und Vertrieb
    • Produktion und Dienstleistungen
  • R&D
    R&D Dedicated to innovation in vaccine research and development Mehr lesen
    • Pipeline
    • Lyme Borreliose – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access-Richtlinie
    • Wissenschaftliche Publikationen
  • Investoren
    Investoren Mehr lesen
    • Events und Präsentationen
      • Kalender
      • Präsentationen des Unternehmens
    • Financial & Filings
      • Finanzberichte
      • SEC Filings
    • Pressemeldungen
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Vorgeschriebene Informationen
    • Aktieninformation
      • Aktienkurs
      • Analysten
      • Aktionärsstruktur
      • Delisting von der Wiener Börse
    • Hauptversammlungen
      • 2022 Kombinierte Hauptversammlung
      • June 23, 2022 Special Meeting
      • Archiv Hauptversammlungen
    • Videos und Webcasts
    • Häufig gestellte Fragen
    • Kontakt
  • Medien
    Medien Pressemeldungen, Aktuelles und Ressourcen für Medien Mehr lesen
    • Pressemeldungen
    • In den Nachrichten
    • Ressourcen für Medien
    • Medienkontakte
  • Karriere
Kontakt
  • EN
  • FR
  • | DE
Search

In den Nachrichten

January 19, 2023 Nature Biotechnology

Chikungunya and Lyme vaccines make headway

23. Dezember 2022 Precision Vaccinations

Chikungunya Vaccine Candidate Completes BLA Submission to U.S. FDA

6. Dezember 2022 The Pharma Letter

Lyme disease vaccine edging closer with Valneva and Pfizer data

6. Dezember 2022 pharmaphorum.com

Valneva eyes first place in chikungunya vaccine race

October 5, 2022 Endpoints News

After Covid setback, Valneva lines up $100M for Pfizer-allied Lyme disease PhIII

26. September 2022 PharmaLive.com

Valneva in talks with potential partner on second-gen Covid-19 Vaccines

September 9, 2022 Investir

Valneva distribuera le vaccin PreHevbri de VBI Vaccines contre l’hépatite B en Europe

8. September 2022 Slate.com

Can the First Lyme Vaccine in 20 Years Succeed?

August 24, 2022 Precision Vaccinations

This Mosquito-borne Viral Disease May Soon Be Prevented with an Innovative Vaccine

18. August 2022 WHO

The Valneva VLA2001 COVID-19 vaccine: What you need to know

  • 1
  • 2
  • 3
  • …
  • 14

Valneva

  • Über uns
  • Produkte
  • R&D
  • Investoren
  • Medien
  • Karriere
Weitere Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Kontakt
© 2023 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

The information collected through these tracking and performance cookies do not identify any individual visitor.
SAVE & ACCEPT